Please see some useful resources below including the latest Open Orphan plc investor presentation, approved company descriptions, and images which can be used for editorial purposes as long as the connection to Open Orphan / hVIVO / Venn is clearly recognisable. Commercial use is prohibited.
|Open Orphan Investor Presentation||21.09.21||1.5 MB|
Images – hVIVO
|Cathal Friel – Executive Chairman Open Orphan plc||21.7 MB||JPG|
|Dr Andrew Catchpole – hVIVO Chief Scientist||6.6 MB||JPG|
|Adam French – hVIVO Director Laboratory Operations||9.8 MB||JPG|
|Adrian Wildfire – hVIVO Director, Scientific & Business Strategy||3 MB||JPG|
|FluCamp Nurse 1||16.7 MB||JPG|
|hVIVO FluCamp 1||110kb||JPG|
|hVIVO FluCamp 2||2 MB||JPG|
|hVIVO FluCamp 3||2 MB||JPG|
|hVIVO FluCamp 4||2 MB||JPG|
|hVIVO FluCamp 5||2 MB||JPG|
|FluCamp Volunteer 1||23.2 MB||JPG|
|Whitechapel Clinic Quarantine Room 1||13.6 MB||JPG|
|hVIVO Lab 1||20.9 MB||JPG|
|hVIVO Lab 2||9 MB||JPG|
|hVIVO Lab 3||18.7 MB||JPG|
|hVIVO Lab 4||17.2 MB||JPG|
|Open Orphan Logo||157KB||PNG|
|Venn Life Sciences Logo||126KB||JPG|
Open Orphan Description
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The Company provides services to Big Pharma, biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic and its state-of-the-art 24-bedroom QMB clinic with its highly specialised on-site virology and immunology laboratory. Open Orphan has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of other models. There has been an explosion in the growth of the infectious disease pharmaceuticals market, which is estimated to grow to in excess of $250bn by 2025. The Group is focused on refreshing its existing challenge models and develop new models, such as Malaria, to address the dramatic growth potential of the global infectious disease market.
Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company’s Disease in Motion® platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies.
Open Orphan’s Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company’s Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts.
Download Open Orphan Description (Txt Format 14kb)
For more information please visit our Company Overview page
|Click here to view our latest press releases.|